Merck & Co., Inc. (MRK) Projected to Post Quarterly Earnings on Thursday

Key Points

• Merck & Co., Inc. is expected to report its Q3 2025 earnings on Thursday, October 30th, with projected earnings of $2.37 per share and revenue of $17.0026 billion.
• In its previous earnings announcement on July 29th, Merck reported $2.13 EPS, exceeding estimates and capturing a return on equity of 41.05%.
• Analysts currently hold an average rating of "Hold" on Merck's stock, with a consensus target price of $104.33.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) is expected to be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $2.37 per share and revenue of $17.0026 billion for the quarter. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS.Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 9:00 AM ET.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion for the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. On average, analysts expect Merck & Co., Inc. to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Merck & Co., Inc. Stock Down 0.0%

Shares of MRK opened at $87.60 on Thursday. The company has a market capitalization of $218.81 billion, a P/E ratio of 13.50, a PEG ratio of 0.96 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $107.36. The business's 50 day simple moving average is $84.28 and its 200-day simple moving average is $81.43.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on MRK shares. Citigroup started coverage on Merck & Co., Inc. in a report on Monday, October 13th. They issued a "neutral" rating and a $95.00 target price on the stock. Berenberg Bank downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Morgan Stanley reduced their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. Finally, Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. has an average rating of "Hold" and a consensus target price of $104.33.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co lifted its position in Merck & Co., Inc. by 16.4% during the second quarter. CANADA LIFE ASSURANCE Co now owns 3,632,893 shares of the company's stock worth $287,781,000 after acquiring an additional 511,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Merck & Co., Inc. by 111.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock worth $53,918,000 after acquiring an additional 359,356 shares during the last quarter. Quantinno Capital Management LP lifted its position in Merck & Co., Inc. by 23.3% during the second quarter. Quantinno Capital Management LP now owns 404,940 shares of the company's stock worth $32,055,000 after acquiring an additional 76,495 shares during the last quarter. Voleon Capital Management LP lifted its position in Merck & Co., Inc. by 95.8% during the second quarter. Voleon Capital Management LP now owns 135,003 shares of the company's stock worth $10,687,000 after acquiring an additional 66,070 shares during the last quarter. Finally, Captrust Financial Advisors lifted its position in Merck & Co., Inc. by 4.6% during the second quarter. Captrust Financial Advisors now owns 1,224,274 shares of the company's stock worth $96,914,000 after acquiring an additional 54,245 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company's stock.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.